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Purpose: The purpose of this study was to examine the expression of the anti-
inflammatory protein Annexin A1 (AnxA1) in mice and human retinae during uveitis
and to determine whether local administration of human recombinant AnxA1
(hrAnxA1) can suppress uveitis in mice.
Methods: Retinal sections from mice (healthy normal and uveitis) and postmortem
human (no history of eye disease (n ¼ 5) and uveitis (n ¼ 7)) were stained for AnxA1
expression and imaged by immunofluorescence microscopy. AnxA1 cellular
expression was determined by colabeling with CD45, glial fibrillary acidic protein
(GFAP), and Iba-1 cells, with additional staining of AnxA1 receptors formyl peptide
receptor 1 (FPR1) and FPRL1/FPR2. Mice with acute endotoxin-induced uveitis and
chronic experimental autoimmune uveitis were treated locally by intravitreal injection
with hrAnxA1, and disease was assessed by clinical scoring and quantification of
leukocyte infiltrate via flow cytometry.
Results: Constitutive expression of AnxA1 was observed in both healthy mouse and
human retinae, and its expression increased during uveitis compared to healthy
controls. AnxA1 colocalizes predominantly with CD45þ cells, GFAPþ macroglia, and to
a lesser extent, Iba-1þ myeloid cells. We also demonstrate that local treatment with
hrAnxA1 attenuates the severity of uveitis in mice.
Conclusions: These data indicate that locally expressed AnxA1 is elevated in the
retina during intraocular inflammation. We demonstrate that local administration of
hrAnxA1 to augment levels results in suppression of uveitis in mice.
Translational Relevance: Our data suggest that elevated expression of retinal AnxA1
in human uveitis may be immunoregulatory and that local supplementation with
hrAnxA1 may provide a potential novel treatment for inflammatory eye diseases such
as noninfectious uveitis.
Introduction
Annexin A1 (AnxA1) plays many roles in cell
physiology and is both highly conserved across
species and widely distributed across many cell types
and biological fluids.1 AnxA1 binds to membrane
acidic phospholipids in the presence of Ca2þ, playing
important intracellular membrane/actin–cytoskele-
tal-associated roles such as granule fusion and
exocytosis, as well as extracellular and secreted roles
such as marking apoptotic neurons for phagocyto-
sis,2 enhancing islet insulin secretion,3 modulating
acute and chronic inflammation,4 and exhibiting
altered expression linked to tumor progression.5
AnxA1 contributes to immune regulation by acting
in part as a key mediator of glucocorticoid action in
cells of the innate immune system.6 AnxA1 acts in
the anti-inflammatory/proresolution arm of the
innate response by moderating leukocyte adhesion
and migration, cytokine production, and histamine
release, promoting neutrophil apoptosis and stimu-
lating their removal by macrophages (for reviews see
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Refs. 7–9). AnxA1 is also expressed at low levels by
T cells,10 and we previously reported that AnxA1-
deficient mice possess an increased Th17 autoim-
mune T-cell response that can drive experimental
autoimmune uveitis (EAU) in mice.11 Concomitant-
ly, we reported that systemic administration of
human recombinant AnxA1 (hrAnxA1) could ame-
liorate EAU in mice by reducing STAT3 phosphor-
ylation and subsequently limiting the peripheral
generation of pathogenic Th17 cells.11 The potential,
then, of AnxA1 to act upon both innate and adaptive
arms of the immune response makes it an attractive
therapeutic candidate for human autoimmune dis-
eases such as uveitis, where macrophages, neutro-
phils, and T cells are known to participate in retinal
damage.12–14 Sight-threatening noninfectious uveitis
is a heterogeneous group of disorders characterized
by intraocular inflammation and is thought to effect
approximately 4 million people globally.15 Current
systemic treatments, including corticosteroids, T-
cell–targeting agents such as cyclosporine, and more
recently TNF antagonists, may induce disease
remission, but they remain limited by the accrual
of significant side effects with the requirement of
chronic use that leads to loss of efficacy.16,17
Therefore, there remains an unmet need for new
uveitis therapies and a need for noncorticosteroid
local therapies.18 While systemic administration of
hrAnxA1 and its mimetic peptides have proven
successful in suppressing multiple preclinical models
of human inflammatory disease,4 the efficacy of local
administration of hrAnxA1 for the treatment of
intraocular inflammation has not been fully ex-
plored. In this study, we assessed the extent of
constitutive AnxA1 expression in the eye and showed
that AnxA1 levels are significantly elevated in the
retina during uveitis in both mice and patients
compared to healthy controls. In inflamed human
retinae, we detect AnxA1 in infiltrating CD45þ
leukocytes, glial fibrillary acidic proteinþ (GFAPþ)
macroglia, and in Iba-1þmyeloid cells. Furthermore,
we showed the presence of two receptors of AnxA1,
formyl peptide receptors 1 (FPR1), and FPRL1/
FPR2 in human retinal tissue. To investigate the
potential efficacy of local administration of AnxA1
in ocular inflammation, we administered hrAnxA1
by intravitreal injection in mice with uveitis and
observed reduced retinal damage and a reduced
burden of leukocyte infiltration. Taken together,
these data support that intraocular administration of
exogenous hrAnxA1 in patients with uveitis may
have an impact on both infiltrating leukocytes and
the retinal tissue itself, corroborating this approach
as a therapy for the treatment of noninfectious
posterior uveitis.
Results
AnxA1 in the Mouse Retina
First we used immunohistochemistry to assess the
basal level of endogenous AnxA1 in the healthy
C57BL/6 mouse retina, confirming a previous re-
port19 that it is most abundant in the ganglion cell
and nerve fiber layers, with some staining observed in
the RPE (Fig. 1A). Western blot analysis revealed
full-length 37-kDa AnxA1 protein from both lysed
and nonlysed whole eyes, suggesting the presence of
soluble secreted AnxA1 within the eye (Supplemental
Fig. 1). We then assessed the levels of AnxA1 in the
retina at peak of EAU disease in C57BL/6 mice (d26)
and observed a considerable increase in AnxA1
staining throughout the retina (Fig. 1B). AnxA1
levels appeared to increase within the ganglion cell
layer (GCL) and RPE compared with basal levels,
and staining was now observed in the outer nuclear
layer (ONL) and photoreceptor layer (PRL) (Fig. 1B).
Quantification of AnxA1 staining confirmed our
observations, showing a significant increase in the
levels of AnxA1 in the retina during C57BL/6 EAU
(Fig. 1C).
AnxA1 in the Human Retina
We next assessed the levels of AnxA1 in the human
retina from both healthy controls and patients with
noninfectious uveitis. The pattern of staining was
similar to that observed in the mouse eye. AnxA1 was
found predominantly in the ganglion and nerve fiber
layers (Fig. 2A), with some staining observed in the
inner nuclear layer and some perivascular staining
around superficial blood vessels that could be retinal
endothelium.20 Quantification of AnxA1 staining
throughout the retina revealed a significant increase
in the levels of AnxA1 in the retina from noninfec-
tious uveitis patients compared to that from healthy
controls (Fig. 2B, C).
AnxA1 Levels Correlate with Inflammatory
Markers in Human Uveitis Retinae
We further analyzed healthy retinae and tissue
from uveitis patients to assess changes in the level and
distribution of AnxA1 during ocular inflammation.
2 TVST j 2017 j Vol. 6 j No. 5 j Article 10
Gardner et al.
Downloaded From: http://tvst.arvojournals.org/pdfaccess.ashx?url=/data/journals/tvst/936467/ on 01/17/2018
Costaining with CD45 revealed the presence of
infiltrating leukocytes both in the vitreous and
throughout retinal layers. All CD45þ cells observed
expressed AnxA1 (Fig. 3). Immunostaining using
AnxA1 and GFAP-specific antibodies revealed Anx-
A1þ macroglia in the ganglion/nerve fiber layer in
healthy retinae that are likely to be retinal astrocytes
and Mu¨ller glia (Fig. 4). In uveitis tissue, a marked
increase in GFAP staining throughout the GCL,
inner plexiform layer (IPL), INL, and ONL was
observed compared to that in healthy tissue. The
increased GFAP in the GCL and IPL largely
colocalized with AnxA1 staining, again indicating
that activated macroglia express AnxA1 (Fig. 4).
However the colocalization of AnxA1 with GFAP in
the INL and ONL appeared variable across eyes from
uveitis patients (Fig. 4). While the number of cells
coexpressing AnxA1 and GFAP was evidently in-
creased in uveitis tissue compared to healthy controls,
the proportion of GFAPþ cells coexpressing AnxA1
was qualitatively decreased in disease. This suggests a
differential expression of AnxA1 by macroglia sub-
types that warrants future investigation. Similarly,
expression of Iba-1, a myeloid marker of microglia
and macrophages, was elevated in uveitis tissue
compared to healthy tissue (Fig. 5A). While Iba-1
staining also increased in uveitis tissue (Fig. 5B), the
proportion of Iba-1þ cells coexpressing AnxA1
remained constant at approximately 60% (Fig. 5C)
(healthy mean 60.01 6 9.181, n ¼ 4; uveitis mean
53.57 6 10.79, n ¼ 3).
Figure 1. Level of endogenous AnxA1 in the C57BL/6 mouse retina is elevated during uveitis (EAU). AnxA1 was stained by
immunohistochemistry (with Triton X-100) on retinal sections cut from eyes of C57BL/6 naı¨ve steady-state mice (n¼3) (A) and those from
peak EAU mice (n¼6) (B). INL, inner nuclear layer; Cb, ciliary body. (C) Quantification of retinal AnxA1 staining compared between steady-
state and peak EAU. Each data point represents the mean of three random sections per eye 6 SEM, *P , 0.05 Student’s t-test. Scale bars:
30 lm.
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Local Administration of hrAnxA1 Attenuates
Acute and Chronic Uveitis in Mice
Human recombinant AnxA1 shares approximately
88% amino acid sequence identity with rodent
AnxA1.21 Both full-length hrAnxA1 and the AnxA1
N-terminal peptide (Ac2–26) have been administered as
a pharmacologic treatment for inflammation in several
mouse models.22 We therefore used hrAnxA1 to assess
the anti-inflammatory role of AnxA1 in the eye and to
assess the therapeutic potential of hrAnxA1 in uveitis.
Firstly, single administration of hrAnxA1 by intravit-
real injection in lipopolysaccharide (LPS)-induced
endotoxin-induced uveitis (EIU) in C57BL/6 mice
showed a dose-response reduction of neutrophils
infiltrating into treated eyes compared to PBS-treated
eyes at peak EIU (18 hours). Neutrophils were
significantly reduced at the 500-ng dose (Fig. 6A).
We then examined whether local injection of hrAnxA1
could suppress the rapid antigen-specific T-cell–medi-
ated disease observed in IRBP peptide–induced EAU
in B10.RIII mice and exploited the reproducible and
Figure 2. Level of endogenous AnxA1 in the human retina is elevated during uveitis. AnxA1 was stained by immunohistochemistry
(with Triton X-100) on retinal sections cut from eyes of healthy donors (A) or uveitis patients (B). (C) Quantification of retinal AnxA1
staining compared between healthy and uveitis patients; each data point represents the mean of three random sections per eye 6 SEM,
***P , 0.001 Mann-Whitney U test. Scale bars: 50 lm.
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validated readouts of clinical assessment score and
flow cytometric assessment of retinal infiltrate previ-
ously reported.23–26 Following clinical confirmation of
disease at day 9 by fundus examination that revealed
optic disc swelling (Fig. 6B), mice received 500 ng/hour
AnxA1 by intravitreal injection in one eye and an in-
jection of PBS in the contralateral eye. Analysis under-
taken at peak disease (day 12) by fundus examination
and flow cytometry for quantification of infiltrating
leukocyte subsets revealed suppression of clinical
disease signs (Fig. 6C) and reduced leukocyte burden
in the hrAnxA1-treated eyes compared to controls
(Fig. 6D). Analysis of leukocyte subsets revealed
significant suppression of total myeloid CD11bþ cells,
specifically Ly6Gþ neutrophils (Fig. 6D).
The AnxA1 Target Receptors FPR1 and
FPRL1/FPR2 Are Expressed in Human Retinae
Since administration of hrAnxA1 suppresses uveitis
in mice, elevated expression of endogenous AnxA1in
the retina following inflammation could be an attempt
at immune regulation by the immunologically privi-
leged retina. It has been previously established that
CD45þ leukocytes express FPRs that act to mediate
signaling by secreted AnxA1.27 In neutrophils, AnxA1
signaling acts to inhibit their extravasation into
inflamed tissues and downregulate their proinflamma-
tory cytokine production.28 While infiltrating leuko-
cytes may be the target of elevated levels of AnxA1 in
the retina during inflammation, it is not known if
retinal cells have the capacity to respond to AnxA1.
Given the marked increase in AnxA1 expression in
both the inflamed mouse and human retina, we sought
to determine whether FRPs are expressed in the human
eye. Leukocytes are known to express FPRs,27,29 but
FPR expression has yet to be examined in the human
retina. Staining of retinal sections revealed the presence
of both FPR1 and FPRL1/FPR2 in healthy (Fig. 7A)
and uveitis retinae (Fig. 7B). FPR1-positive staining
was observed in the GCL, ONL, and photoreceptors
(Fig. 7A and B). FPRL1/FPR2-positive staining was
observed in the GCL, IPL, and photoreceptors (Fig.
7A and B). While the pattern of staining was similar
for both FPRs in healthy and uveitis tissue, increased
staining was observed in some uveitic eyes, particularly
in the iris, a location where infiltrating leukocytes are
known to enter the eye from the periphery (Fig. 7B).30
Discussion
Our examination of AnxA1 expression in the eye
has revealed the association of elevated levels of
AnxA1 protein with inflammation in both mouse
and human retinal tissue. This supports the rele-
vance of using mouse models of uveitis to study
AnxA1 biology in inflammatory disease. AnxA1 is
known to participate in proresolution pathways of
inflammation,4 and we therefore postulate that
elevated AnxA1 expression in the retina is an
attempted regulatory response to ocular inflamma-
tion and infiltrating leukocytes. This notion is
further supported by the suppression of disease in
mice with uveitis following local administration of
hrAnxA1.
Figure 3. Colocalization of AnxA1 with CD45þ leukocytes in human uveitis retinae and vitreous. AnxA1 and CD45 were stained by
immunohistochemistry on retinal sections cut from eyes of uveitis patients. Scale bars: 50 lm.
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Study of AnxA1 in the brain has revealed an
important role of AnxA1 in regulating blood–brain
barrier function through endothelium tight-junction
integrity,31 and AnxA1 is also thought to carry out
possible neuroprotective roles.32,33 AnxA1 expres-
sion in the human CNS is almost exclusive to
microglia,2 hence we examined expression of AnxA1
in retinal microglia. In the retina, however, elevated
levels of AnxA1 were found in GFAPþ macroglia
(astrocytes and Mu¨ller glia), but only in a proportion
of Iba-1þ myeloid cells. The upregulation of AnxA1
in astrocytes and microglia has been reported in rats
during EAE,34,35 similar to our EAU data, and it has
also been reported that microglia but not astrocytes
secrete AnxA1,36 perhaps explaining why supple-
mentation of endogenous AnxA1 with hrAnxA1 can
effectively suppress uveitis in mice. Of note, our data
show similarities with reports showing elevated
expression of AnxA1 in brains of Alzheimer’s,37
multiple sclerosis,38 and Parkinson’s disease39 pa-
tients, suggesting conserved roles of AnxA1 across
neural tissue. The potential impact of AnxA1
modulation for ocular diseases (other than uveitis)
that exhibit an inflammatory component is also of
note, with reports of the ability of exogenous
hrAnxA1 to modulate mast cells40,41 and suppress
allergic conjunctivitis in mice42 and the association
of the inactive form of AnxA1 in tears from active
vernal keratoconjunctivitis patients compared to
controls.43
AnxA1 is known to mediate some aspects of
glucocorticoid-mediated immune suppression,44 and
Figure 4. Colocalization of AnxA1 with GFAP in human retinae. AnxA1 and GFAP were stained by immunohistochemistry (with Triton X-
100) on retinal sections cut from healthy donor eyes and uveitis patients. Scale bars: 50 lm.
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glucocorticoid steroids are the current frontline
treatment for noninfectious uveitis patients.45 The
attractiveness of locally administered hrAnxA1 as a
therapeutic lies in the possibility of delivering the
benefits of glucocorticoid steroids without the side
effects,46 although this exact mechanism is yet to be
determined and will require future work to identify
the specific retinal cell types expressing FPRL1/FPR2
receptors for AnxA1 and a characterization of their
response to exogenous hrAnxA1. Our data confirm
and extend a previous report where elevated AnxA1
expression was observed in rodent EIU, and topical
application of an AnxA1 mimetic peptide suppressed
EIU infiltration through the FPRL1/FPR2 recep-
tor.19 Our data compliment those reported by Girol
and colleagues19 by confirming the relevance of
AnxA1 in human retinae and by revealing successful
treatment of the T-cell–driven EAU mouse model
using hrAnxA1. We also report, we believe for the
first time, the expression of the target receptors, FPR1
and FPRL1/FPR2, receptors of AnxA1 in human
retinae. FPRL1/FPR2 is known to mediate signals
from AnxA1, lipoxin A(4), and serum amyloid A to
regulate inflammation.27 Retinal expression of
FPRL1/FPR2 in astrocytes, microglia, and Mu¨ller
glia may allow hrAnxA1 to modulate the retinal tissue
itself (in addition to infiltrating leukocytes), perhaps
via downregulation of chemokine production, and
thus may explain the potent local effects of hrAnxA1
we observed in mouse models of uveitis. While FPR1
has mainly been studied in neutrophil migration, it is
known to be expressed by non-hematopoietic cells
with as yet unknown biological function,47 and hence
the significance of expression in the human retina is
unknown. While our data are encouraging with
respect to the therapeutic potential of hrAnxA1 for
Figure 5. Colocalization of AnxA1 with Iba-1 in human retinae. (A) AnxA1 and Iba-1 were stained by immunohistochemistry (with Triton
X-100) on retinal sections cut from healthy donor eyes and uveitis patients. White box indicates magnified region; the white boxes show
magnified region (B) quantification of Iba-1 pixels in healthy compared to uveitis eyes. Each data point represents the mean of three
random sections per eye 6 SEM; Mann-Whitney U test. (C) Quantification of the colocalization of AnxA1 signal with Iba-1 in healthy
compared to uveitis eyes; each data point represents the mean of three random sections per eye 6 SEM. Scale bars: 50 lm.
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treating uveitis, further work is required to examine
the potential for (adverse) downstream AnxA1
signaling events following hrAnxA1 administration.
In summary, this study has shown AnxA1 is
significantly elevated in mouse and human uveitic
retinae. Furthermore, we have demonstrated effective
treatment for both acute and chronic uveitis in mice
by local administration of full-length hrAnxA1. This
provides proof of concept for a novel therapeutic
approach for the treatment of patients with nonin-
fectious uveitis.
Methods
Animals
All mouse procedures were conducted under the
regulation of the UK Home Office Animals (Scientific
Figure 6. Local administration of hrAnx-A1 suppresses uveitis in mice. (A) Quantification by flow cytometry of neutrophils
(CD45þCD11bþLy6Gþ) infiltrating the eye at peak EIU disease (18 hours post induction) following administration of 2 lL PBS vehicle or
hrAnxA1 (50 ng and 500 ng, respectively) by intravitreal injection. Data representative of two independent experiments, n¼ 5–7 mice 6
SEM, **P , 0.05 Kruskal-Wallis multiple comparison test; ns, not significant. (B) Representative fundus images of EAU mice day 4–12 post
induction having been treated at day 10 with a single 2-lL injection of PBS vehicle in one eye or 500 ng hrAnx-A1 in the contralateral eye.
(C) Clinical scoring of fundus imaging of B10.RIII EAU mice at peak disease (day 12). Data presented as mean 6 SEM, n¼5 mice/group; *P
, 0.05 paired t-test. (D) Graphs showing quantification by flow cytometry of total CD45þ leukocytes, total CD11bþ counts, CD11bþLy6Cþ
(monocytes/macrophages), and C11bþLy6Gþ (neutrophils) from individual eyes of EAU mice treated with PBS vehicle and 500 ng AnxA1.
Data presented as mean 6 SEM, n ¼ 5 mice/group, *P , 0.05 paired t-test.
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Procedures) Act 1986, with University College Lon-
don Ethics Committee approval and in compliance
with the Association for Research in Vision and
Ophthalmology (ARVO) statement for the Use of
Animals in Ophthalmology and Vision Research.
Wild-type C57BL/6J female mice aged between 6 and
10 weeks were used.
Human Ocular Tissue
Healthy adult (age 18–65 years) human postmor-
tem eyes from anonymous donors collected by
Moorfields Biobank following corneal removal for
transplantation (n ¼ 5) and noninfectious uveitis
patient eyes (described in Supplementary Table S1)
collected by Moorfields Biobank (n ¼ 6 post mortem
and n¼ 1 enucleation) were fixed in 10% formalin and
embedded in paraffin wax. Use of human tissue for
this project was supported by NIHR funding and
approved by the NHS Research Ethics Committee
(10/H0106/57-14ETR41).
EAU Induction
Six-week-old C57BL/6 mice or B10.RIII mice (as
indicated in the Results and figure legends) were
immunized in the flank with 500 lg RBP1–20 and 300
lg RBP161–180, respectively, in PBS emulsified with
complete Freund’s adjuvant (Sigma-Aldrich Corp.,
Gillingham, UK) supplemented with 1.5 mg/mL
Figure 7. FRPs are expressed in human retinae. FPR1 and FPRL1/FPR2 were stained by immunohistochemistry on retinal sections cut
from (A) healthy donor eyes and (B) uveitis patients. Due to the primary antibodies being raised in the same species, FPR1 was stained
first alone, followed by its secondary antibody, followed by staining with the directly conjugated FPRL1/FPR2 AF647 antibody.
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Mycobacterium tuberculosis complete H37 Ra (Difco
Microbiology, Lawrence, KS) (1:1 vol/vol). The mice
also received 1.5 lg Bordetella pertussis toxin (Sigma-
Aldrich Corp.) intraperitoneally.
EIU Induction
Disease was induced in C57BL/6 mice following
induction of general anesthesia using ketamine by
administration of 1 ng LPS (lipopolysaccharides from
Escherichia coli O55:B5; Sigma-Aldrich Corp.) dis-
solved in PBS by intravitreal injection of 2 lL using a
microsurgical syringe and 38-gauge needle (Hamilton,
Giarmata, Romania).
hrAnxA1 Administration
hrAnxA1 was diluted in PBS and delivered directly
to the eye by intravitreal injection of 2 lL at the stated
quantities (for the case of EAU) or diluted 1:1 with
LPS (1 lg/mL) at the stated quantities and delivered
by 2-lL intravitreal injection at EIU induction.
Fundus Imaging
The topical endoscopic fundus imaging (TEFI)
system was used for routine in vivo imaging of mouse
retinal fundus as previously described.48 Clinical
scoring of TEFI images was carried out using a modi-
fied scoring system that has been previously de-
scribed.48
Immunohistochemistry and Fluorescent
Imaging
Human ocular 3-lm sections were cut and dewaxed
in histoclear (National Diagnostics, Atlanta, GA),
rehydrated, and subjected to antigen retrieval using
antigen unmasking solution (H-3300; Vector Labs,
Peterborough, UK) with pressure cooker heating for 2
minutes after achieving rich full pressure (13 Pa), prior
to blocking and staining. Mouse eyes were enucleated
and fixed in 4% paraformaldehyde for 1 hour before
freezing in OCT medium (Fisher Scientific, Lough-
borough, UK) and 16-lm cryosections cut. Sections
were blocked in 5% donkey serum (with and without
0.2% Triton X-100, as indicated) for 1 hour prior to
staining with rabbit anti-AnxA1 (ab196830; Abcam,
Cambridge, UK), goat anti-AnxA1 (ab115770; Ab-
cam), mouse anti-human GFAP (M0761; Dako, Santa
Clara, CA), mouse anti-human CD45 (M0701, Dako),
rabbit anti-Iba-1 (019-19741; Wako, Neuss, Germany),
rabbit anti-FPRL1/FPR2 (NLS1878AF647; Novus
Biologicals, Littleton, CO), rabbit anti-human FPR1
(NBP2-47452; Novus Biological), and the appropriate
secondary antibodies: goat anti-rabbit IgG (HþL)
Alexa Fluor 488 (A-11008; Life Technologies, Carls-
bad, CA), donkey anti-goat IgG (HþL) Alexa Fluor
488 (A-11055; Life Technologies), goat anti-mouse IgG
(HþL) Alexa Fluor 546 (A-11030; Life Technologies),
goat anti-rabbit IgG (HþL) Alexa Fluor 546 (A-11010;
Life Technologies). No primary antibody control
stains were carried out for all secondary antibodies
on mouse and human tissue (Supplemental Fig. 2).
Sections were stained with DAPI (D1306; Life
Technologies) with appropriate washing steps prior
to imaging with a confocal microscope (DM5500Q;
Leica, Wetzlar, Germany). Quantification of fluores-
cent pixels was carried out following file conversion to
FCS files using FlowJo software (Treestar, Ashland,
OR).
Flow Cytometry
Enucleated eyes were dissected in 100 lL cold
Dulbecco’s modified Eagle’s medium. After incision
at the limbus with a 29-gauge needle, a circumferen-
tial cut around the eye following the limbus was
made. Iris was dissected, releasing anterior chamber
infiltrating cells into the dissection media. The retina
and vitreous were then removed carefully from the eye
cup, leaving the sclera/retinal pigment epithelium/
choroid intact. The dissection media containing
anterior fluid, vitreous, and retina were then pipetted
into a 1.5-mL Eppendorf tube and mechanically
disrupted by rapping 10 times for a single-cell
suspension, followed by centrifugation through a 70-
lm cell strainer. The resulting single-cell suspensions
were blocked with anti-mouse CD16/32 (2.4G2;
eBioscience, Waltham, MA) for 5 minutes prior to
surface staining with the following antibodies: aGr1-
APC, aLy6C-PE, aCD11b-PerCP, aCD45-FITC,
APC-efluor780 live dead dye. Absolute cell numbers
were obtained as previously detailed25 using a BD
LSR Fortessa-x20 with FACSDiva software (version
8.1; BD Cytometry Systems, San Jose, CA). Single-
stained beads (OneComp eBeads; eBioscience) of all
fluorophores were used to generate compensation
matrices, and fluorescence-minus-one controls were
used for positive gating; data were analyzed using
FlowJo software (Treestar).
Western Blot
Detection of AnxA1 was carried out on whole
mouse eye homogenate. Enucleated mouse eyes were
homogenized with a micropestle and mortar tube
10 TVST j 2017 j Vol. 6 j No. 5 j Article 10
Gardner et al.
Downloaded From: http://tvst.arvojournals.org/pdfaccess.ashx?url=/data/journals/tvst/936467/ on 01/17/2018
(Eppendorf) in cold PBS and spun to remove cells or
in RIPA buffer containing 1:100 freshly added
protease inhibitor cocktail (Sigma-Aldrich Corp.),
freeze-thawed, and spun to remove cellular material.
Proteins were separated using an 8% SDS-PAGE gel
and blotted to a transfer membrane (Immobilon-P;
Millipore, Watford, UK), followed by detection with
rabbit anti-AnxA1 (ab196830; Abcam), then by
incubation with the secondary antibody swine anti–
rabbit-HRP (P0399; Dako) and subsequent develop-
ment with a detection kit (ECL Plus; Amersham, GE
Healthcare, Amersham, UK).
Statistical Analysis
Data were analyzed for statistical significance
using statistical analysis software (GraphPad Inc.,
La Jolla, CA).
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